1-2 of 2
Randy Davis, PhD
Close
Sort by
Journal Articles

DREAMM-8: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin with Pomalidomide and Dexamethasone (B-Pd) Vs Pomalidomide Plus Bortezomib and Dexamethasone (PVd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Suzanne Trudel, MD, Randy Davis, PhD, Nicole M. Lewis, MSc, Kalpana K. Bakshi, MSc, Bikramjit Chopra, PhD, Rocio Montes de Oca, PhD, Geraldine Ferron-Brady, PhD, Laurie Eliason, MPH, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Frank S. Wu, MDPhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 4.
https://doi.org/10.1182/blood-2020-139785
Published: 2020
Journal Articles

DREAMM-7: A Phase III Study of the Efficacy and Safety of Belantamab Mafodotin (Belamaf) with Bortezomib, and Dexamethasone (B-Vd) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Robert M. Rifkin, MD, Kevin Boyd, MB BS, BSc, MRCP, FRCPath, PhD, Sebastian Grosicki, MD PhD, Kihyun Kim, MD PhD, Francesco Di Raimondo, MD, Meletios A Dimopoulos, Katja Weisel, MD, Bertrand Arnulf, MD, Roman Hajek, MD, Vania T. M. Hungria, MD PhD, Andrew Spencer, Randy Davis, PhD, Antonio Riccio, PhD MBA, Chanbin Kim, Jodie Wilkes, Ruth Rutledge, Mala Talekar, MD, Brandon E. Kremer, MD PhD, Ira Gupta, MD, Maria-Victoria Mateos, MD PhD
Journal: Blood
Blood (2020) 136 (Supplement 1): 53–54.
https://doi.org/10.1182/blood-2020-139181
Published: 2020